Vaxcyte, Inc.(PCVX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PCVX Vaxcyte, Inc.

盘后交易 02-26 18:08:51 EST

60.00

-3.04

-4.82%

盘后61.19

+1.19+1.98%

18:04 EST

最高62.73	最低59.16	成交量198.69万
今开61.67	昨收63.04	日振幅5.66%
总市值86.40亿	流通市值70.18亿	总股本1.44亿
成交额1.20亿	换手率1.70%	流通股本1.17亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PCVX","market":"US","secType":"STK","nameCN":"Vaxcyte, Inc.","latestPrice":60,"timestamp":1772139600000,"preClose":63.04,"halted":0,"volume":1986914,"hourTrading":{"tag":"盘后","latestPrice":61.19,"preClose":60,"latestTime":"18:04 EST","volume":323404,"amount":19404269.10636,"timestamp":1772147089920,"change":1.19,"changeRate":0.019833,"amplitude":0.019833},"delay":0,"changeRate":-0.04822335025380709,"floatShares":116968635,"shares":144000000,"eps":-5.63,"marketStatus":"盘后交易","change":-3.04,"latestTime":"02-26 18:08:51 EST","open":61.67,"high":62.73,"low":59.16,"amount":119770957.35946,"amplitude":0.056631,"askPrice":61.19,"askSize":31,"bidPrice":58.84,"bidSize":33,"shortable":3,"etf":0,"ttmEps":-5.63,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772154000000},"marketStatusCode":4,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":63.04,"preHourTrading":{"tag":"盘前","latestPrice":63.15,"preClose":63.04,"latestTime":"09:25 EST","volume":2396,"amount":151305.44726000002,"timestamp":1772115900536,"change":0.11,"changeRate":0.001745,"amplitude":0.066624},"postHourTrading":{"tag":"盘后","latestPrice":61.19,"preClose":60,"latestTime":"18:04 EST","volume":323404,"amount":19404269.10636,"timestamp":1772147089920,"change":1.19,"changeRate":0.019833,"amplitude":0.019833},"volumeRatio":1.568554,"impliedVol":0.5187,"impliedVolPercentile":0.1394},"requestUrl":"/m/hq/s/PCVX","defaultTab":"news","newsList":[{"id":"1115709239","title":"异动解读 | 获TD Cowen大幅上调目标价，Vaxcyte盘中大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115709239","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115709239?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:57","pubTimestamp":1772031444,"startTime":"0","endTime":"0","summary":"Vaxcyte, Inc. (PCVX) 今日盘中大幅上涨5.09%，引起了市场的广泛关注。消息面上，根据路透社发布的华尔街分析师研究报告摘要，投行TD Cowen将Vaxcyte的目标价从50美元大幅上调至75美元，上调幅度高达50%。此举反映了分析师对公司未来前景的乐观态度，通常被视为积极的信号，从而提振了投资者信心，推动了股价在交易时段内的显著上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PCVX"],"gpt_icon":0},{"id":"1118115432","title":"Vaxcyte公司签订销售协议，可不时出售最高达5亿美元的普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1118115432","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118115432?lang=zh_cn&edition=full","pubTime":"2026-02-25 06:25","pubTimestamp":1771971925,"startTime":"0","endTime":"0","summary":"Vaxcyte公司宣布，已正式签订一项股权销售协议。根据该协议，公司未来可能不定期地在市场上出售其普通股股票，总出售金额最高可达5亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","PCVX","BK4139","IE0009354923.USD"],"gpt_icon":0},{"id":"1146755858","title":"财报前瞻｜Vaxcyte, Inc.本季度营收预计为零，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1146755858","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146755858?lang=zh_cn&edition=full","pubTime":"2026-02-17 11:08","pubTimestamp":1771297705,"startTime":"0","endTime":"0","summary":"Vaxcyte, Inc.将于2026年02月24日发布最新季度财报，市场关注研发表现与费用节奏对每股亏损的影响。市场一致预期显示，本季度Vaxcyte, Inc.的营收预计为0.00美元；调整后每股收益预计为-1.55美元，同比-35.67%；息税前利润预计为-2.43亿美元，同比-56.88%。近期关注Vaxcyte, Inc.的卖方研究更偏向谨慎立场，看空与看多观点对比中，持偏谨慎观点占较大比例。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Vaxcyte, Inc.本季度营收预计为零，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"gpt_icon":0},{"id":"1171154453","title":"Vaxcyte启动Opus-3三期临床试验，为首批曾接种低效价肺炎疫苗的成人受试者接种Vax-31","url":"https://stock-news.laohu8.com/highlight/detail?id=1171154453","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171154453?lang=zh_cn&edition=full","pubTime":"2026-02-12 05:06","pubTimestamp":1770843973,"startTime":"0","endTime":"0","summary":"生物制药公司Vaxcyte, Inc.（纳斯达克代码：PCVX）宣布，其针对成人肺炎链球菌疫苗的Opus-3三期临床试验已取得重要进展，首批曾接种过低效价肺炎疫苗的参与者已成功接种候选疫苗Vax-31。这项关键性研究旨在评估Vax-31在该特定人群中的免疫原性及安全性表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX","LU0053671581.USD","BK4139","IE0009354923.USD"],"gpt_icon":0},{"id":"1191902800","title":"Vaxcyte将于2026年2月24日公布2025年第四季度及全年财务业绩并举行业务进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1191902800","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191902800?lang=zh_cn&edition=full","pubTime":"2026-02-11 05:06","pubTimestamp":1770757575,"startTime":"0","endTime":"0","summary":"生物技术公司Vaxcyte, Inc.近日宣布，公司计划于2026年2月24日发布其2025年第四季度及全年的财务业绩报告。此次公告不仅将详细披露关键财务数据，还将同步更新公司最新的业务进展与战略规划。\n投资者与市场分析师可通过官方渠道获取具体财报发布时间及电话会议接入信息，届时管理层将现场解读业绩表现并回应市场关切。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX","BK4139","IE0009354923.USD","LU0053671581.USD"],"gpt_icon":0},{"id":"2608083158","title":"Vaxcyte, Inc.盘中异动 股价大涨5.02%报56.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608083158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608083158?lang=zh_cn&edition=full","pubTime":"2026-02-03 01:47","pubTimestamp":1770054433,"startTime":"0","endTime":"0","summary":"北京时间2026年02月03日01时47分，Vaxcyte, Inc.股票出现波动，股价大幅拉升5.02%。截至发稿，该股报56.26美元/股，成交量95.7949万股，换手率0.73%，振幅5.40%。Vaxcyte, Inc.股票所在的生物技术行业中，整体涨幅为0.57%。Vaxcyte, Inc.公司简介：Vaxcyte Inc 是一家临床阶段的疫苗创新公司，致力于开发高保真疫苗，以保护人类免受细菌性疾病的危害。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203014714a474298d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203014714a474298d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","IE0009354923.USD","BK4139","PCVX"],"gpt_icon":0},{"id":"1137869121","title":"Vaxcyte预计2027年上半年公布Opus-2与Opus-3两项三期研究的安全性、耐受性及免疫原性顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1137869121","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137869121?lang=zh_cn&edition=full","pubTime":"2026-01-23 06:02","pubTimestamp":1769119352,"startTime":"0","endTime":"0","summary":"Vaxcyte宣布，计划于2027年上半年同步披露其Opus-2与Opus-3两项关键三期临床试验的顶线研究结果。这些数据将重点呈现疫苗在人体内的安全性表现、受试者耐受程度以及激发的免疫反应水平，为后续监管审批提供核心依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX","IE0009354923.USD","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1101203872","title":"Vaxcyte：Vax-31成人三期非劣效性试验（Opus-1）持续招募受试者，关键数据预计2026年第四季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1101203872","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101203872?lang=zh_cn&edition=full","pubTime":"2026-01-23 06:01","pubTimestamp":1769119281,"startTime":"0","endTime":"0","summary":"Vaxcyte, Inc. 宣布，其针对成人群体开展的Vax-31三期非劣效性临床试验（代号Opus-1）目前正按计划持续推进受试者招募工作。该试验旨在评估疫苗的免疫效果，公司预期将于2026年第四季度获得并公布关键的顶线数据结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","PCVX","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"2602486304","title":"Vaxcyte, Inc.盘中异动 快速拉升5.08%报47.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602486304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602486304?lang=zh_cn&edition=full","pubTime":"2026-01-09 23:28","pubTimestamp":1767972481,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日23时28分，Vaxcyte, Inc.股票出现波动，股价急速拉升5.08%。截至发稿，该股报47.62美元/股，成交量12.4483万股，换手率0.10%，振幅3.24%。Vaxcyte, Inc.股票所在的生物技术行业中，整体涨幅为1.12%。Vaxcyte, Inc.公司简介：Vaxcyte Inc 是一家临床阶段的疫苗创新公司，致力于开发高保真疫苗，以保护人类免受细菌性疾病的危害。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109232801a707f0a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109232801a707f0a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","BK4139","IE0009354923.USD","PCVX"],"gpt_icon":0},{"id":"1111364809","title":"Vaxcyte启动Opus 3期非劣效性试验，首批参与者接种Vax-31以预防成人侵袭性肺炎球菌疾病和肺炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1111364809","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111364809?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:03","pubTimestamp":1765195402,"startTime":"0","endTime":"0","summary":"Vaxcyte启动Opus 3期非劣效性试验，首批参与者接种Vax-31以预防成人侵袭性肺炎球菌疾病和肺炎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX","LU0053671581.USD","BK4139","IE0009354923.USD"],"gpt_icon":0},{"id":"1113364352","title":"Vaxcyte, Inc.：Vax-24婴儿二期剂量发现研究最终数据与之前报告的积极中期数据一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1113364352","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113364352?lang=zh_cn&edition=full","pubTime":"2025-11-05 06:29","pubTimestamp":1762295355,"startTime":"0","endTime":"0","summary":"Vaxcyte, Inc.：Vax-24婴儿二期剂量发现研究最终数据与之前报告的积极中期数据一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","LU0053671581.USD","PCVX","BK4139"],"gpt_icon":0},{"id":"2572520556","title":"Vaxcyte, Inc.盘中异动 临近收盘股价大涨5.05%报36.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572520556","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572520556?lang=zh_cn&edition=full","pubTime":"2025-10-01 03:31","pubTimestamp":1759260660,"startTime":"0","endTime":"0","summary":"北京时间2025年10月01日03时31分，Vaxcyte, Inc.股票出现波动，股价快速上涨5.05%。截至发稿，该股报36.40美元/股，成交量162.151万股，换手率1.25%，振幅5.95%。Vaxcyte, Inc.股票所在的生物技术行业中，整体涨幅为0.92%。Vaxcyte, Inc.公司简介：Vaxcyte Inc 是一家临床阶段的疫苗创新公司，致力于开发高保真疫苗，以保护人类免受细菌性疾病的危害。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001033100a44f113a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001033100a44f113a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","PCVX","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1166747804","title":"Vaxcyte于9月24日与赛默飞世尔旗下Patheon Manufacturing Services LLC签署协议 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1166747804","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166747804?lang=zh_cn&edition=full","pubTime":"2025-09-30 21:19","pubTimestamp":1759238373,"startTime":"0","endTime":"0","summary":"Vaxcyte于9月24日与赛默飞世尔旗下Patheon Manufacturing Services LLC签署协议 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670627923.USD","BK4121","LU1064131342.USD","BK4139","LU0528227936.USD","LU1988902786.USD","LU0053671581.USD","LU2041044095.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4548","IE0009354923.USD","LU0114720955.EUR","LU2211814178.USD","IE00B19Z8X17.USD","BK4566","LU0882574055.USD","LU1923622614.USD","LU2298321311.HKD","LU2468319806.SGD","LU0096362180.USD","LU2125909247.SGD","LU2092937221.SGD","LU2764263203.CNY","BK4533","LU1983299246.USD","LU1712237335.SGD","LU1923622291.USD","IE00B1BXHZ80.USD","LU2720916845.USD","LU0011850046.USD","LU1791710400.SGD","LU2264538146.SGD","LU0234572021.USD","LU1061106388.HKD","LU0557290698.USD","LU1548497426.USD","BK4588","IE0034235188.USD","LU0061474960.USD","IE00B19Z9505.USD","LU2125909759.SGD","LU1720051017.SGD","BK4535","LU0316494557.USD","LU2764262908.HKD","LU1023059063.AUD","BK4585","LU0640476718.USD","IE00B19Z8W00.USD","LU1057294990.SGD","LU1153585028.USD","LU1854104046.USD","LU1815333072.USD","IE00B4R5TH58.HKD","IE0009355771.USD","LU1623119135.USD","LU2357305700.SGD","LU2433249047.HKD","LU1989771016.USD","LU2125910179.SGD","LU0957791311.USD","BK4581","LU2125909593.SGD","LU1670628061.USD","LU2125910336.SGD","LU2360108059.USD","LU1854103824.USD","LU2211815571.USD","IE00B2B36J28.USD","PCVX","LU0823416689.USD","BK4534","LU1720051108.HKD","LU0266013472.USD","LU0122379950.USD","LU1923621640.USD","IE00BJJMRZ35.SGD","GB00BDT5M118.USD","LU2089984988.USD","LU2764263039.SGD","LU1791710582.SGD","LU2063271972.USD","IE00BKPKM429.USD","LU0342679015.USD","LU1291159041.SGD","LU2112291526.USD","IE0002141913.USD","LU1280957306.USD","TMO","LU1803068623.USD","LU1633808545.USD","LU2125909916.SGD"],"gpt_icon":0},{"id":"1115291761","title":"Vaxcyte公司计划在2027年上半年末发布初次免疫系列和加强剂量的关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1115291761","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115291761?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:32","pubTimestamp":1756899141,"startTime":"0","endTime":"0","summary":"Vaxcyte公司表示，计划在2027年上半年结束前发布初次免疫系列和加强剂量的关键数据，这些数据可能会按顺序发布或同时发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4139","LU0053671581.USD","PCVX"],"gpt_icon":0},{"id":"1138438764","title":"Vaxcyte, Inc.推进Vax-31婴儿2期剂量探索研究，首批受试者已接受优化剂量给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1138438764","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138438764?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:32","pubTimestamp":1756899136,"startTime":"0","endTime":"0","summary":"Vaxcyte, Inc.宣布其Vax-31婴儿2期剂量探索研究取得进展，首批参与试验的受试者已开始接受Vax-31优化剂量的给药治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","IE0009354923.USD","PCVX"],"gpt_icon":0},{"id":"2517346929","title":"Vaxcyte, Inc.盘中异动 快速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517346929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517346929?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:45","pubTimestamp":1741207533,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时45分，Vaxcyte, Inc.股票出现波动，股价快速上涨5.10%。Vaxcyte, Inc.股票所在的生物技术行业中，整体涨幅为1.97%。Vaxcyte, Inc.公司简介：Vaxcyte Inc 是一家疫苗公司，致力于通过开发新型疫苗来治疗患有最常见和致命疾病的患者，从而改善全球健康状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306044533a2612eba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306044533a2612eba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","BK4139","PCVX","LU0053671581.USD"],"gpt_icon":0},{"id":"2516552206","title":"Vaxcyte, Inc.2024财年实现净利润-4.64亿美元，同比减少15.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516552206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516552206?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:01","pubTimestamp":1740844868,"startTime":"0","endTime":"0","summary":"3月2日，Vaxcyte, Inc.公布财报，公告显示公司2024财年净利润为-4.64亿美元，同比减少15.42%；其中营业收入为0.00美元，每股基本收益为-3.80美元。从资产负债表来看，Vaxcyte, Inc.总负债2.27亿美元，其中短期债务5.89百万美元，资产负债比为15.57，流动比率为12.78。机构评级：截至2025年3月2日，当前有9家机构对Vaxcyte, Inc.目标价做出预测，其中目标均价为150.22美元，其中最低目标价为135.00美元，最高目标价为163.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000148abe2c5d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000148abe2c5d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCVX"],"gpt_icon":0},{"id":"2514333298","title":"Vaxcyte, Inc.盘中异动 下午盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514333298","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514333298?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:07","pubTimestamp":1740686870,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时07分，Vaxcyte, Inc.股票出现波动，股价快速下跌5.08%。Vaxcyte, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，Pepgen Inc.、Ibio, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1919.08%、338.83%、188.69%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Vaxcyte, Inc.公司简介：Vaxcyte Inc 是一家疫苗公司，致力于通过开发新型疫苗来治疗患有最常见和致命疾病的患者，从而改善全球健康状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228040750a256c504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228040750a256c504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","BK4139","IE0009354923.USD","PCVX"],"gpt_icon":0},{"id":"2509350942","title":"Vaxcyte, Inc.盘中异动 早盘股价大涨5.00%报90.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509350942","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509350942?lang=zh_cn&edition=full","pubTime":"2025-02-06 00:18","pubTimestamp":1738772301,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日00时18分，Vaxcyte, Inc.股票出现波动，股价急速拉升5.00%。截至发稿，该股报90.84美元/股，成交量15.0673万股，换手率0.12%，振幅3.92%。Vaxcyte, Inc.股票所在的生物技术行业中，整体涨幅为1.36%。Vaxcyte, Inc.公司简介：Vaxcyte Inc 是一家疫苗公司，致力于通过开发新型疫苗来治疗患有最常见和致命疾病的患者，从而改善全球健康状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206001821987b8e87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206001821987b8e87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PCVX","IE0009354923.USD","LU0053671581.USD"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FWONK","PAYX","HQY","INSM","TROW","FER","HLNE","LI","NVIW.SI","TRMB","TPG","AEP","LU2065731478.USD","TLN","EQIX","FCNCA","MKTX","CSX","ZS","SOFI","CSCO","BK4581","CDNS","CBSH","ILMN","COIN","LU0053671581.USD","MDLZ","PARA","TCOM","EWBC","MANH","TTEK",".IXIC","RYAAY","DLTR","GRAB","SQQQ","FFIV","INCY","LNW","PLTR","HTHT","COKE","ALAB","MRVL","AMZN","LU1815336091.USD","HBAN","CEG","GLPI","MDB","BKNG","AMAT","FYBR","TXN","CHKP","BK4550","TECH","WWD","QLD","WYNN","ENTG","BKR","LSCC","CDW","ITCI","ADSK","CCEP","NXPI","AZN","TSLA","NBIX","ALGN","BK4086","GMAB","ONC","LNT","ESLT","EA","MNQmain","JKHY","CHRD","HOOD","CHTR","ICLR","HST","BRKR","NDAQ","NWSA","ZM","TEAM","COO","EVRG","WBA","NVMI","TER","AMGN","AGNC","PCTY","CFLT","RKLB","META","EXAS","TSCO","SEIC","TSEM","FOXA","ORLY","NTNX","RADX","DKNG","TTD","NTRA","AFRM","CZR","STX","NICE","CHDN","BK4593","ADI","NVDA","ANSS","ADBE","CTSH","DASH","FTAI","QCOM","AUR","NTES","PSQ","ON","SIRI","EBAY","TQQQ","BPOP","FTNT","BK4534","AVGO","LSTR","CWST","LU0757428866.USD","BSY","ERIE","AAPL","MTSI","INTC","SAIA","OTEX","NDSN","ASML","MSFT","FOX","LULU","CINF","BPMC","NTRS","ROP","ROST","WTFC","KDP","FSLR","QXO","RPRX","AXON","CHRW","SWKS","ODFL","GEHC","AMD","QQQ","MNST","DDOG","PAA","USAW.SI","MKSI","EXPE","DOX","JD","CG","AAL","CPB","PCVX","QID","HON","MIDD","RIVN","Z","AAON","BIIB","BK4561","PNFP","HSIC","MRNA","DOCU","PDD","CYBR","DPZ","NTAP","MTCH","QRVO","ALNY","ENPH","GOOGL","MMYT","MELI","LECO","LOGI","SBUX","NQmain","FAST","BK4588","BMRN","LIN","MARA","MEDP","CTAS","USJW.SI","PFG","POOL","KHC","CSGP","CRWD","EXE","REGN","PCAR","TSYW.SI","BK4585","ERIC","AKAM","LAMR","GTLB","OLED","GILD","CSWI","ROIV","OKTA","CME","CPRT","GEN","DSGX","DUOL","CASY","MPWR","ISRG","PODD","LKQ","APA","ARM","GNTX","JBHT","RGEN","ARGX","IDXX","ROKU","SSNC","TMUS","STLD","MCHP","INTU","SRPT","TTWO","FSV","COST","RGLD","RVMD","SBAC","TW","LPLA","SMCI","FRPT","REG","ULTA","PTC","HOLX","NFLX","SNPS","SFM","MNDY","WDC","PEP"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.vaxcyte.com","stockEarnings":[{"period":"1week","weight":0.1223},{"period":"1month","weight":0.1805},{"period":"3month","weight":0.2697},{"period":"6month","weight":1.0474},{"period":"1year","weight":-0.2055},{"period":"ytd","weight":0.3663}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vaxcyte, Inc.于2013年11月27日在特拉华州注册成立。该公司是一家下一代疫苗公司，旨在通过开发预防或治疗全球某些最常见和致命的传染病的新型疫苗来改善全球健康状况。他们的无细胞蛋白质合成平台使他们能够设计和生产蛋白质载体和抗原，这是疫苗的关键组成部分。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.007757},{"month":2,"riseRate":0.5,"avgChangeRate":0.019656},{"month":3,"riseRate":0.2,"avgChangeRate":-0.152425},{"month":4,"riseRate":0.4,"avgChangeRate":-0.015793},{"month":5,"riseRate":0.6,"avgChangeRate":0.069759},{"month":6,"riseRate":0.8,"avgChangeRate":0.011811},{"month":7,"riseRate":0.5,"avgChangeRate":0.011479},{"month":8,"riseRate":0.833333,"avgChangeRate":0.13264},{"month":9,"riseRate":0.5,"avgChangeRate":0.090313},{"month":10,"riseRate":0.333333,"avgChangeRate":0.104582},{"month":11,"riseRate":0.5,"avgChangeRate":-0.025818},{"month":12,"riseRate":0.5,"avgChangeRate":0.007817}],"exchange":"NASDAQ","name":"Vaxcyte, Inc.","nameEN":"Vaxcyte, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vaxcyte, Inc.(PCVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Vaxcyte, Inc.(PCVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Vaxcyte, Inc.,PCVX,Vaxcyte, Inc.股票,Vaxcyte, Inc.股票老虎,Vaxcyte, Inc.股票老虎国际,Vaxcyte, Inc.行情,Vaxcyte, Inc.股票行情,Vaxcyte, Inc.股价,Vaxcyte, Inc.股市,Vaxcyte, Inc.股票价格,Vaxcyte, Inc.股票交易,Vaxcyte, Inc.股票购买,Vaxcyte, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vaxcyte, Inc.(PCVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Vaxcyte, Inc.(PCVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}